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E-mail: fulvio.mavilio@unimore.itSickle cell disease (SCD) is caused by a mutation (E6V) in the
hemoglobin (Hb) b-chain that induces polymerization of Hb
tetramers, red blood cell deformation, ischemia, anemia, and
multiple organ damage. Gene therapy is a potential alternative
to human leukocyte antigen (HLA)-matched allogeneic he-
matopoietic stem cell transplantation, available to a minority
of patients. We developed a lentiviral vector expressing a
b-globin carrying three anti-sickling mutations (T87Q,
G16D, and E22A) inhibiting axial and lateral contacts in the
HbS polymer, under the control of the b-globin promoter
and a reduced version of the b-globin locus-control region.
The vector (GLOBE-AS3) transduced 60%–80% of mobilized
CD34+ hematopoietic stem-progenitor cells (HSPCs) and
drove bAS3-globin expression at potentially therapeutic levels
in erythrocytes differentiated from transduced HSPCs from
SCD patients. Transduced HSPCs were transplanted in
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)-immunodeficient
mice to analyze biodistribution, chimerism, and transduction
efficiency in bone marrow (BM), spleen, thymus, and periph-
eral blood 12–14 weeks after transplantation. Vector integra-
tion site analysis, performed in pre-transplant HSPCs and
post-transplant BM cells from individual mice, showed a
normal lentiviral integration pattern and no evidence of clonal
dominance. An in vitro immortalization (IVIM) assay showed
the low genotoxic potential of GLOBE-AS3. This study enables
a phase I/II clinical trial aimed at correcting the SCD pheno-
type in juvenile patients by transplantation of autologous
hematopoietic stem cells (HSC) transduced by GLOBE-AS3.
INTRODUCTION
Sickle cell disease (SCD) is caused by a mutation in the sixth amino
acid of the hemoglobin (Hb) b-chain (E6V), which causes polymeri-
zation of Hb tetramers upon deoxygenation. As a consequence, red
blood cells (RBCs) lose flexibility and adopt the characteristic sickle
shape in the capillary circulation, causing ischemia, stroke, multi-
organ damage, severe pain, chronic hemolytic anemia, and reduced
life expectancy.1 SCD is endemic in Africa and frequent in the West-Molecular Therapy: Methods & Clin
This is an open access article under the CC BY-NC-ern world: approximately 100,000 individuals in the USA and 10,000
in France are affected by the disease, with an incidence of 1:5,000 and
1:2,500, respectively. Current treatment includes regular blood trans-
fusions and induction of fetal Hb (HbF) synthesis by hydroxyurea.2,3
The only definitive therapy for SCD is allogeneic transplantation of
hematopoietic stem cells (HSCs) from matched sibling donors, with
a reported disease-free survival rate of >90% at 6 years after transplan-
tation.4 Transplants with matched unrelated or mismatched donors
carry progressively higher, unacceptable risks for morbidity and
mortality.4 Given the large variability in clinical severity, the limited
availability of suitable donors, and the toxicity associated with the
procedure, HSC transplantation is not frequently performed on
SCD patients, particularly in the adult age. Gene therapy, i.e., trans-
plantation of autologous HSCs genetically corrected with a lentiviral
vector (LV) expressing an anti-sickling globin chain, could be a ther-
apeutic option with less treatment-related morbidity, theoretically
available to all patients. Hematopoietic stem-progenitor cells
(HSPCs) transduced by LVs have been used in clinical trials of gene
therapy for immunodeficiencies, lysosomal storage disorders, and he-
moglobinopathies, providing strong evidence of clinical efficacy in the
absence of treatment-related adverse events.5
Allogeneic HSC transplantation provides predictions about the min-
imal level of corrected HSCs and anti-sickling Hb synthesis necessary
to achieve clinical benefit in SCD patients. Stable mixed chimerism
with donor HSC levels as low as 10%–30% leads to significant clinical
improvement, because of the selective survival of normal, donor-
derived RBCs with respect to HbS-containing RBCs.6–8 On the other
hand, SCD patients carrying a hereditary persistence of HbF (HPFH)ical Development Vol. 11 December 2018 ª 2018 The Authors. 167
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Transduction of Human Mobilized CD34+
HSPCs by the GLOBE-AS3 Vector
(A) Scheme of the GLOBE-AS3 lentiviral vector: the human
bAS3-globin gene is under transcriptional control of a short
(264-bp) b-globin promoter (b-p) and an HS2+HS3mini LCR
in anti-sense orientation in the CCL-SIN-18 LV backbone. Ex
1, 2, and 3 indicate the three b-globin exons. The three
mutations are indicated in red. (B and C) Transduction effi-
ciency of GLOBE-AS3 at increasingMOI in G-CSF-mobilized
CD34+ HSPCs from five healthy donors, maintained for
2 weeks in liquid myeloid (B, left panel) or erythroid (B, right
panel) culture, or cultured as individual progenitors (C) in
semi-solid medium. (D) At day 14 of erythroid differentiation,
cells were collected and the expression of bAS3 mRNA was
determined by qRT-PCR as ratio between bAS3 mRNA and
the endogenous a-globin mRNA, and correlated with VCN.
Molecular Therapy: Methods & Clinical Developmentexperience a much milder clinical course or are asymptomatic.9,10
Together, these data suggest that engraftment of >20% of autologous
HSCs producing an RBC progeny with >30% anti-sickling Hb levels
could ameliorate the SCD pathology.
Pre-clinical and clinical studies have shown the potential of gene ther-
apy in correcting the SCD phenotype. The LVs used in these studies
express either the fetal g-globin or mutant b-globins that interfere
with axial and lateral contacts in the HbS polymer, thereby reducing
HbS polymerization and sickling. The anti-sickling genes are ex-
pressed under the control of a b-globin promoter and combinations
of elements from the b-globin locus control region (LCR) for
maximal gene expression.11 An LV expressing one such mutant, the
bAT87Q, is currently used in clinical trials for both b-thalassemia
and SCD.12,13 A second mutant, bAS3 globin, carries the T87Q and
two additional mutations, G16D and E22A, which contribute to the
anti-sickling activity and increase the affinity of the mutant for the
a chain.14 bAS3 globin, expressed in the context of an LV, corrects
a murine model of SCD15 and reduces the level of HbS and RBC sick-
ling at potentially therapeutic levels when transferred in bone marrow
(BM)-derived human CD34+ HSPCs from SCD patients.16,17
Here we present the characterization of an optimized vector (GLOBE-
AS3) expressing the human b-AS3 gene under the control of a short
human b-globin promoter and a reduced version (HS2+HS3) of the
b-globin LCR. This vector design allows high transgene expression
from a minimal size transgene, essential for high-titer vector produc-
tion. As part of the pre-clinical validation of the vector, we analyzed
the in vitro correction of the sickle phenotype in SCD patients’ cells, as
well as engraftment, biodistribution, and in vivo genotoxicity of trans-168 Molecular Therapy: Methods & Clinical Development Vol. 11 December 2018duced human HSPCs from healthy donors after
xenotransplantation in an NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mouse model. A vector inte-
gration analysis was carried out before and after
transplantation, to analyze the clonal dynamics
of transduced cells in vivo, and positive or negative
selection of cells harboring integration events inspecific genes or classes of genes. This study has been designed to
enable a multicenter phase I/II clinical trial aimed at establishing
the safety and efficacy of HSPCs transduced with GLOBE-AS3 for
gene therapy for SCD.
RESULTS
Design of a SIN LV for SCD Gene Therapy
A self-inactivating (SIN) LV (GLOBE-AS3; Figure 1A) was built by
cloning the human bAS3-globin gene under the control of a short
(264-bp) b-globin promoter and a HS2+HS3 mini LCR in anti-sense
orientation in the CCL-SIN-18 LV backbone. The vector was pseu-
dotyped with vesicular stomatitis virus glycoprotein (VSV-G) and
produced by transient transfection in 293T cells with an average
infectious titer of 3.5  109 transducing units (TU)/mL. Transduc-
tion efficiency was tested on CD34+ HSPCs mobilized with granulo-
cyte-colony stimulating factor (G-CSF) in the peripheral blood (PB)
of five healthy donors. HSPCs were transduced at increasing MOI
(50, 100, and 200) and maintained for 2 weeks in liquid culture sup-
porting myeloid or erythroid differentiation, or cultured as individ-
ual progenitors (colony-forming cells [CFCs]) in semi-solid me-
dium. The average vector copy number (VCN) in the myeloid
bulk cultures of transduced CD34+ cells was 0.7 ± 0.2, 0.9 ± 0.3,
and 0.9 ± 0.2 (mean ± SEM), respectively, whereas it reached
1.3 ± 0.3, 1.8 ± 0.3, and 1.9 ± 0.3 in erythroid cultures (Figure 1B).
The % of transduced individual CFCs (myeloid + erythroid + mixed
colonies) was 49% at the highest MOI (Figure 1C). At day 14 of
erythroid differentiation, 80% of cells were positive for the
erythroid markers CD36 and CD235a (data not shown). Cells
were collected, total RNA was extracted, and the expression of
bAS3 mRNA determined by qRT-PCR as a ratio between bAS3
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Figure 2. Correction of the Sickling Cell Phenotype In Vitro in Erythrocytes Expressing bAS3 Globin
(A) Average VCN in CD34+ HSPCs from the BM of seven different SCD patients after transduction with GLOBE-AS3 at different MOIs (25–500), measured 2 weeks after
transduction. (B) Quantification of HbAS3 tetramers by HPLC in a red blood cell (RBC) lysate. (C) Correlation between VCN and HbAS3 synthesis. Extrapolation of the
correlation curve (R = 0.8305) estimates an output of 11 ng of HbAS3 per vector copy per cell. (D) The histogram shows the relative proportion of AS3, sickling (S), and fetal (F)
hemoglobins in erythrocytes differentiated from CD34+ cells with increasing VCN. (E) In vitro anti-sickling assay in erythrocytes differentiated in culture from BM CD34+ cells
from a representative SCDdonor. RBCs derived from cells transduced with GLOBE-AS3 showed a percentage of phenotypically corrected, non-sickled forms proportional to
the VCN.
www.moleculartherapy.orgmRNA and the endogenous a-globin mRNA (HbA). Relative bAS3
expression was correlated to the VCN, achieving between 4% and
30% of the a-globin expression with VCN values ranging from 0.6
to 2.5 (Figure 1D).
Expression of bAS3 Globin in RBCs from SCD Patients and
Correction of the Sickle Cell Phenotype In Vitro
CD34+ HSPCs were obtained from the BM of seven different SCD
patients, transduced with GLOBE-AS3 at different MOIs (25–500),
and maintained in erythroid cultures for 3 weeks. The VCN,
measured 2 weeks after transduction, ranged between 0.3 and 3.8,
with a substantial variability in cells from different donors trans-
duced at similar MOI (Figure 2A), indicating a significant donor-
dependent variability in transduction efficiency. After 3 weeks of
culture, cells were harvested and the amount of vector-driven
HbAS3 protein quantified by high-pressure liquid chromatography
(HPLC) in RBC lysates (Figure 2B). A high correlation was observed
between VCN and HbAS3 protein production (R = 0.8305; Fig-
ure 2C), with an estimated output of 11 ng of HbAS3 per integrated
vector copy.Molecular TheThe effect of the synthesis of bAS3 globin on the SCD phenotype was
tested by an in vitro anti-sickling assay in erythrocytes differentiated
in culture from BM CD34+ cells from one SCD donor. CD34+ cells
were transduced at MOIs of 45, 150, and 450 and cultured for 3 weeks
in erythroid differentiation medium to obtain hemoglobinized,
enucleated RBCs. Cells were harvested and incubated in sealed cham-
bers with sodium metabisulfite to induce sickling as previously
described.16 Cell morphology was then examined under a phase-
contrast microscope. RBCs derived from cells transduced with
GLOBE-AS3 showed a higher percentage of phenotypically corrected,
non-sickled forms compared with RBCs derived from mock-trans-
duced cells from the same donor (Figure 2D). The percentage of
phenotypically corrected cells correlated with VCN, reaching a
maximum of 34.0% at a VCN of 1.7 (Figure 2D).
Transplantation of Human G-CSF-Mobilized CD34+ Cells
Transduced with LV-bAS3 in NSG Mice
CD34+ HSPCs were mobilized by G-CSF from three healthy donors,
pre-activated overnight with a cytokine cocktail, and either mock-
transduced or transduced by two rounds of infection at MOI 100rapy: Methods & Clinical Development Vol. 11 December 2018 169
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Figure 3. Transplantation of G-CSF-Mobilized CD34+ Cells Transduced with LV-bAS3 in NSG Mice
(A) Scheme of the in vivo study. CD34+ HSPCs from three healthy donors were mock-transduced or transduced with GLOBE-AS3, or with a control vector expressing GFP
and transplanted in sub-lethally irradiated female NSG recipient mice. (B) Human cell chimerism (left panel) and average VCN in the donor cell fraction (right panel) were
evaluated in the BM of mice 12 weeks after transplantation. Animals transplanted with cells coming from two independent transductions with GLOBE-AS3 (TD1 and TD2)
are identified by red diamonds or triangles, respectively, and individual mice are identified by numbers. (C) The presence of human T (left panel), B (center panel), and
myeloid (right panel) cells was evaluated by flow cytometry after immunostaining for human CD45+/CD3+, CD45+/CD19+, and CD45+/CD33+ cells, respectively. Bars
indicate mean ± SEM. Statistical significance was calculated by a Mann-Whitney test: *p < 0.05. n.s., not significant.
Molecular Therapy: Methods & Clinical Developmentwith GLOBE-AS3 or with a control vector expressing GFP from the
human phosphoglycerate kinase promoter (PGK-GFP). We per-
formed two independent transductions, the first with CD34+ cells
from one donor (TD1) and the second with cells pooled from two
different donors (TD2). An aliquot of cells transduced with
GLOBE-AS3 was maintained in liquid culture for a week for VCN
evaluation and vector integration analysis or cultured as individual
progenitors in semi-solid medium for 2 weeks. A VCN of 2.8 ± 0.2
and 4.7 ± 0.8 was obtained with GLOBE-AS3 and PGK-GFP, respec-
tively, with 51% and 75% of transduced individual progenitors. Cells
transduced with PGK-GFP were also analyzed for GFP expression
by flow cytometry, resulting in 60.0% ± 9.0% GFP+ cells. After trans-
duction, CD34+ cells were transplanted in sub-lethally irradiated,
female NSG recipient mice (10 mice per group) by retro-orbital
injection (2  106 cells/mouse) (Figure 3A). Transplanted mice170 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemwere maintained for 3 months and monitored weekly for health
and body weight. One mouse that received untransduced cells and
two mice that received cells transduced with GLOBE-AS3 were
sacrificed at an early time point because of loss of weight due to the
irradiation, with no significant difference among the three groups
(c2 test, p = 0.3). White blood cell (WBC), RBC, and platelet counts
were determined at sacrifice and showed no apparent difference
among the three groups (Figure S1A).
At the end of the study, human cell chimerism was evaluated in the
BM by flow cytometry after labeling with a human-specific anti-
CD45 antibody. Engraftment of human cells was comparable in
mice receiving cells transduced by the GLOBE-AS3 or by the control
vector (Figure 3B). The average VCN/donor cell of the test group was
0.4, showing efficient transduction of repopulating stem cells by theber 2018
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Figure 4. In Vitro Immortalization Assay
Proliferating clones were detected by MTT absorbance measurements in 96-well
plates. Replating frequencies (RF) were calculated according to Poisson statistics.
Each dot represents one assay. Values between the limit of detection (LOD) and
the quantification threshold (Q1) were defined as background. All plates with
clonal proliferation >Q1 were counted as positive. The negative assays below LOD
were manually inserted into the graph. Bars indicate means. Statistical differences
were calculated with a Fisher’s exact test: *p < 0.05. Dagger (z) indicates a sample
with a very low VCN of 0.12. All other GLOBE-AS3 samples had an average VCN of
6.5 ± 0.5.
www.moleculartherapy.orgGLOBE-AS3 vector (Figure 3B). The average VCN was significantly
lower than that obtained in cells transduced with the PGK-GFP
vector, reflecting the lower transduction efficiency measured in pre-
transplant cells. The presence of human T, B, and NK cells was eval-
uated by flow cytometry after immunostaining for human CD45+/
CD3+, CD45+/CD19+, and CD45+/CD56+ cells, respectively. No sig-
nificant difference in engraftment of immune cells was detected in the
three groups of mice, with animals showing either predominant B cell
or predominant T cell engraftment (Figure 3C; mice in the GLOBE-
AS3 group are individually identified), a pattern reproduced also in
PB and spleen (Figure S1B, top and middle panels). In animals where
a thymus could be analyzed, this showed a high proportion of CD4+/
CD8+ double-positive T cells, with no difference among the three
groups (Figure S1B, bottom panel). As expected for this mouse model,
engraftment of CD45+/CD33+ myelomonocytic cells was <10% in all
hematopoietic organs (Figures 3C and S1B, top and middle panels),
with no significant difference among the three groups. Overall, histo-
pathological analysis of hematopoietic and non-hematopoietic organs
revealed comparable size, cellularity, and organ architecture in mice
receiving untransduced cells or cells transduced with either vector.
No malignancy was observed in any of the groups (data not shown).Molecular TheAnalysis of the In Vitro Genotoxic Potential of the GLOBE-AS3
Vector
We tested the insertional mutagenesis potential of the GLOBE-AS3
vector in three independent in vitro immortalization (IVIM)
assays.18,19 As a positive control for vector-induced immortalization,
we included a mutagenic gammaretroviral vector with intact LTRs.
Non-transduced cells (Mock) were the negative control. Mutagenic,
LTR-driven vectors like RSF91 contain strong enhancer-promoter
sequences and can activate proto-oncogenes near the insertion
sites.20 In the IVIM assay, these mutants show a proliferation
advantage when cells are seeded at very low density. While
non-immortalized cells stop growing, insertional mutants can be
quantified by their replating phenotype on a 96-well plate. We
used a cumulative MOI of 400 in two rounds of transduction
for GLOBE-AS3 and achieved a VCN of 6.5 ± 0.5 in 10 out of
11 transductions. One sample had a very low VCN of 0.12 for
unknown reason. The positive control RSF91 reached VCN values
of 8.8 ± 2.1. After transduction of 1  105 starting cells, cultures
were expanded for 2 weeks and then re-plated at 100 cells/96-well
plate. For RSF91, we observed insertional mutants in seven out of
nine transductions with a mean replating frequency (RF) of 4.1 
103. In contrast, the GLOBE-AS3 vector showed a significantly
lower incidence of positive plates (2 out of 11; p = 0.022, Fisher’s
exact test) and an over 10-fold lower RF in the IVIM assay, which
was statistically not different from non-transduced Mock cells
(RF = 1.08  104; p = 0.05, Kruskal-Wallis test with Dunn’s correc-
tion) (Figure 4). Hence, GLOBE-AS3 showed a low risk for induc-
tion of insertional mutagenesis, even with multiple integrated
proviral copies.
Analysis of the Integration Profile of GLOBE-AS3 in Human G-
CSF-Mobilized CD34+ HSPCs
The global integration characteristics of the GLOBE-AS3 vector were
determined on an aliquot of transduced human HSPCs before trans-
plantation. Integration sites (ISs) were recovered by linker-mediated
PCR (LM-PCR) followed by high-throughput Illumina sequencing
and mapped to the human genome (hg19 assembly) by a previously
described, custom-designed bioinformatic pipeline21 (Figure 5A).
The aim of the analysis was to compare pre- and post-transplantation
integration profiles to uncover differences in integration characteris-
tics or frequency and function of the targeted gene pool that may sug-
gest altered dynamics in the hematopoiesis of transplanted mice
caused by positive or negative selection of cells harboring specific
integration events.
The integration profile of GLOBE-AS3 in pre-transplant CD34+ cells
was analyzed in each transduction and in the merged TD1+TD2 data-
set. Sequencing of the LM-PCR libraries generated 2.6–2.8 million
reads/sample, corresponding to about 5.5 million reads in the merged
TD1+TD2 dataset. Overall, a total of 41,979 ISs were retrieved from
pre-transplant CD34+ cells, with 13,459 and 28,721 unique ISs
retrieved from TD1 and TD2 CD34+ cells, respectively (Table 1).
The GLOBE-AS3 vector showed the canonical LV genome-wide inte-
gration profile in CD34+ cells, with a prevalence of intragenic, mostlyrapy: Methods & Clinical Development Vol. 11 December 2018 171
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Figure 5. Integration Profile of GLOBE-AS3 in Human Mobilized CD34+ HSPCs
(A) The genome-wide integration pattern of the GLOBE-AS3 vector was determined on an aliquot of the transduced human HSPCs before transplantation in NSG mice. ISs
were recovered by LM-PCR followed by high-throughput Illumina sequencing, and mapped to the human genome (hg19). (B) Distribution of ISs along the human genome in
pre-transplant CD34+ cells (left bars) and the corresponding post-transplant BM cells (right bars). The proportion of intragenic (intronic or exonic) ISs was significantly
decreased in post-transplant compared with pre-transplant cells (c2 test, ****p < 0.0001). (C) Venn diagram showing the proportion of targeted (left) and over-targeted (right)
genes shared by TD1 (yellow) and TD2 (blue) samples in pre-transplant CD34+ cells. (D) Venn diagram showing the proportion of targeted genes shared by pre-transplant
CD34+ cells and merged post-transplant BM cells in TD1 (left) and TD2 (middle) samples, and by the post-transplant TD1 and TD2 merged samples (right).
Molecular Therapy: Methods & Clinical Developmentintronic ISs (81% in both TD1 and TD2; Figure 5B). Overall, the
41,979 ISs targeted 7,989 genes, corresponding to 28.5% of the anno-
tated human genes. Most of the targeted genes were in common
between TD1 and TD2, with the larger dataset (TD2) including the
majority (77%) of the genes targeted in the smaller one (TD1)
(Figure 5C).
We then analyzed the genes targeted at a statistically significant
(p < 0.001) higher frequency with respect to an in silico-generated
random set of integrations in the human genome, after Bonferroni
correction for false discovery rate. By this analysis, 266 and 415 genes,172 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemrespectively, were significantly over-targeted by GLOBE-AS3 in TD1
and TD2, respectively. Most of the genes over-targeted in TD1 (56%)
were over-targeted also in TD2 (Figure 5C), and among the top-100
over-targeted genes (by IS frequency), 55 were in common between
the TD1 and TD2 datasets (Table S1). The top-100 list contains
most of the genes preferentially targeted by LV integration in HSPCs
of patients treated by gene therapy for hematological and non-hema-
tological disorders (in bold in Table S1). Among the targeted genes
(merged TD1+TD2), several functional categories were enriched by
DAVID analysis (Bonferroni corrected, p % 0.001), and included
metabolism and transport of proteins, RNA and DNA, chromatinber 2018
Table 1. GLOBE-AS3 Integration Sites Retrieved from Pre-transplantation
G-CSF-Mobilized PB CD34+ HSPCs and BM Samples from NSG Mice 3
Months after Transplantation
Sample
Human Chimerism
in BM (% huCD45) VCN No. of ISs
No. of
Target Genes
Pre-transplant CD34+
cells (merged TD1+TD2)
– 2.75 41,979 7,989
TD1 CD34+ cells NA 2.6 13,459 4,814
TD1 BM26 35 0.5 615 359
TD1 BM27 68 0.8 677 479
TD1 BM28 73 0.3 810 536
TD1 BM29 57 0.4 1,018 651
TD1 BM30 63 0.3 949 598
TD1 BM31 30 0.2 1,190 672
TD1 BM cells (merged) 54 0.4 3,822 1,970
TD2 CD34+ cells – 2.9 28,721 6,869
TD2 BM32 13 0.7 2,036 1,300
TD2 BM33 27 0.8 1,729 1,096
TD2 BM34 13 1.9 1,101 720
TD2 BM35 16 0.7 1,013 679
TD2 BM cells (merged) 17 1.0 5,332 2,559
BM cells (merged
TD1+TD2)
– – 8,870 3,595
huCD45, human CD45 antigen.
www.moleculartherapy.orgmodifications, regulation of gene expression, and mitosis (the top-20
categories are listed in the Table S2).
Integration Profile of GLOBE-AS3 in Human NSG-Repopulating
Cells
The integration profile of GLOBE-AS3 was then analyzed in the BM
of each transplanted mouse in the TD1 and TD2 groups, as well as in
the merged TD1+TD2 dataset, and the post-transplantation profiles
compared with the corresponding pre-transplant CD34+ datasets.
Sequencing of the LM-PCR libraries generated 1–2.3 million reads/
sample, corresponding to about 12 million reads in the merged
TD1+TD2 dataset (Table 1). We retrieved between 615 and 2,036
ISs from individual BMs, suggesting a highly polyclonal repopulation
in all transplanted mice (Table 1). On average, TD2 BMs yielded a
higher number of ISs, in line with the higher average VCN observed
in these animals and possibly reflecting a better transduction of the
TD2 CD34+ cells (Table 1).
The global post-transplant LV integration profile showed a preva-
lence of intragenic ISs (71% in TD1 and 78% in TD2), although their
proportion was significantly decreased with respect to the corre-
sponding pre-transplant CD34+ samples (c2 test, p < 0.0001; Fig-
ure 5B), suggesting a negative in vivo selection of cells hosting
intragenic integrations. The difference was significant also when
considering only the integrations in exons (4.88% in the TD1+TD2
pre-transplant CD34+ cells versus 4.44% in the corresponding post-Molecular Thetransplant BM; c2 test, p < 0.0001; values rounded to 5% and 4% in
Figure 5B). No selection for the orientation of the provirus with
respect to the target gene was observed in the post- versus pre-trans-
plant samples (Table S3). Most of the genes hosting a GLOBE-AS3 IS
in the post-transplant BMs were targeted also in the corresponding
pre-transplant CD34+ dataset (68% in TD1 and 85% in TD2; Fig-
ure 5D), and no gene was targeted at a statistically higher frequency
in BM cells (merged TD1+TD2) with respect to the corresponding
pre-transplant samples. Almost half of the targeted genes (Figure 5D)
and 20 out of the top-50 targeted genes were in common between the
TD1 and TD2 BM samples (Table 2), and 23 (46%) and 29 (58%) of
the top-50 targeted genes in TD1 and TD2, respectively, were listed in
the top-100 over-targeted genes in the corresponding pre-transplant
samples (second and fifth columns in Table 2). These data suggest no
substantial positive or negative selection for cells carrying ISs in
specific genes after transplantation. Again, most of the genes
described as preferentially targeted by LV integration in patients
treated by gene therapy are among the 50 top-targeted genes in BM
cells (footnote “a” in Table 2).
A comprehensive functional analysis of the targeted genes in BM cells
(merged TD1+TD2) performed by DAVID indicated no significant
enrichment (Bonferroni-corrected p% 0.01) in functional categories
with respect to the pre-transplant CD34+ cells (merged TD1+TD2)
except for the category “regulation of GTPase activity” (data not
shown). Although no gene was targeted at a statistically higher
frequency in TD1, TD2, and merged TD1+TD2 BM cells with respect
to the corresponding pre-transplant samples, 34 genes were found
enriched (p < 0.05 after Bonferroni correction) in individual BM
samples (Table S4). Among them, only four genes were significantly
enriched with p% 0.001, i.e., ORC4 in BM26, TECR and FHOD1 in
BM28, and NDE1 in BM33 (in bold in Table S4), and none of them
are present in cancer-related gene lists (see Materials and Methods).
Analysis of the Clonal Dynamics in Post-transplant BM Cells
The relative proportion of reads accounting for each individual IS in
the pre- and post-transplant samples was determined and used as an
indirect measure of the relative abundance of individual cell clones,
considering an IS as a surrogate marker of clonality. All the ISs in
pre-transplant CD34+ cells (TD1, TD2, and merged TD1+TD2)
and 88% of the ISs in the post-transplant BM cells (merged
TD1+TD2) were represented by <1% of the total reads (Figure 6),
indicating the largely polyclonal composition of these cell samples.
In the BM of individual mice, some ISs had read counts >1% of the
total reads of the sample (Table S5), possibly reflecting a higher abun-
dance of some NSG-repopulating cell clones at the time of sample
collection. In particular, three ISs showed read counts >10% in the
BM of mice belonging to the TD1 group (Table S5). Overall, this
group showed a less polyclonal BM repopulation and a consequent
over-representation of individual cell clones. These data are in line
with the lower transduction and lower VCN of TD1 CD34+ cells
with respect to TD2 cells (Table 1), and the lower IS recovery in
the BM of individual mice (on average, 876 versus 1,470 ISs/mouse
in TD1- versus TD2-transplanted mice; Figure 6).rapy: Methods & Clinical Development Vol. 11 December 2018 173
Table 2. Top 50 Genes Targeted by GLOBE-AS3 in the BM of NSG Mice
Transplanted with the TD1 and TD2 CD34+ Cells, Ranked by Number of
Independent ISs per Gene
NF1 9 X  EIF4G3 14 X 
EHMT1 8 X  PHACTR4 13  
GRB2 8 X  FCHSD2 12 X 
PACS1 8 X  BRE 11  
ERC1 7   GATAD2B 11 X 
GPATCH8 7 X  NBPF20 11  
KDM2A 7 X  WASF2 11  
NFATC3 7 X  GPATCH8 10 X 
PHACTR4 7 X  MIR1268A 10 X 
ACOX1 6 X  ASH1L 9 X 
ASH1L 6 X  GRB2 9 X 
C6orf10 6   NDE1 9  
FNBP1 6 X  NSD1 9 X 
GATAD2B 6   PBX3 9 X 
IP6K1 6 X  PPP6R2 9 X 
RAB11FIP3 6 X  RAD51B 9  
RERE 6   THADA 9  
SARNP 6 X  CAPN1 8 X 
STK4 6   EHMT1 8 X 
VAV1 6 X  FBXL20 8  
ATF7 5 X  FNBP1 8 X 
C11orf30 5   SMG6 8 X 
EIF4G3 5 X  STAT3 8  
FHOD1 5   STAT5B 8 X 
GON4L 5 X  STK4 8  
LRBA 5   TAOK1 8  
NAALADL2 5   ACOX1 7 X 
NBPF10 5   BLM 7 X 
NBPF9 5   CARD8 7 X 
NFAT5 5   CLIC4 7  
ORC4 5   MGA 7 X 
RPTOR 5   NBAS 7  
ST3GAL3 5 X  NPLOC4 7 X 
TAOK1 5 X  SKAP1 7  
TECR 5   SMG1 7 X 
TRPC4AP 5   SPATS2 7 X 
DIP2B 4   UBR2 7 X 
FOXJ3 4   CEP85 6  
FRY 4   FAM168A 6  
OS9 4   FLYWCH1 6  
POLE 4   NBPF9 6 X 
RABGAP1L 4   NEAT1 6  
RBMS2 4   NFAT5 6 X 
RPRD2 4   NFATC3 6 X 
SBF2 4   RERE 6  
SDHC 4   TMEM57 6  
VPS45 4 X  TTBK2 6 X 
TD1  TD2 
Gene Name No. of ISs 
Shared with TD1 
CD34+ Cells 
 Gene Name No. of ISs 
Shared with TD2 CD34+ 
Cells 
FCHSD2 16 X  PACS1 28 X 
NBPF20 11   KDM2A 18 X 
EYA3 9 X  NF1 17  
For each gene, an X indicates that the gene was also targeted in the respective pre-trans-
plant CD34+ cell sample. Genes targeted in both TD1 and TD2 BM samples are high-
lighted in matching colors. Genes found preferentially targeted by LV integration also in
gene therapy patients are indicated in bold.
Molecular Therapy: Methods & Clinical DevelopmentIn the TD2 group, only one BM sample had an IS with a read count
higher than 5% of the total reads (BM35, chr1, position +153821982
in the GATAD2B gene; Figure 6), whereas all BM samples of the TD1
group showed ISs with read counts >5% of the total reads/sample
(Figure 6). In particular, one IS in the TD1 BM27 sample accounted
for 48% of the total reads, i.e., an intronic insertion in anti-sense
orientation in the FOXP1 gene (chr3, +71173918; Figure 6), a Fork-
head-box transcription factor involved in multiple cell differentiation
pathways during development and differentiation. Neither this IS, nor
any of the other ISs with read count >1% in individual BM samples,
exceed 1% of the reads in the other BM samples of the same TD
group, suggesting a random rather than a consistent, IS-dependent
clonal amplification event.
Overall, 81% of the ISs accounting for >1% of the total reads/sam-
ple were intragenic and targeted 146 genes, which were not en-174 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemriched for gene ontology (GO) categories or KEGG pathways by
DAVID functional analysis and were not included in the list of
genes previously described as enriched in targeting frequency in
the BM of individual mice. These data again suggest a random
rather than integration-driven clonal fluctuation in the BMs of
the transplanted mice.
As expected, only a few of the ISs mapped in the BM samples were
found in the corresponding pre-transplant sample (Figure 7; Table
S6), indicating the exceedingly polyclonal composition of both TD1
and TD2 samples. Interestingly, some ISs were in common among
different mice in each transduction group, suggesting that a certain
number of NSG-repopulating cells expanded in the transduction
culture and were able to repopulate more than one mouse (Figure 7;
Table S6). Contamination between different BM samples was
excluded by the DNA bar coding used in the LM-PCR and sequencing
procedure (see Materials and Methods).
DISCUSSION
SCD is the most frequent monogenic disease worldwide, affecting
millions of individuals.22 Gene therapy, or the autologous transplan-
tation of genetically corrected HSCs, is a potential alternative to
allogeneic HSC transplantation, carrying lower transplant-related
risks and being theoretically available to all patients. LV-transduced
HSPCs have been used in clinical trials of gene therapy for immu-
nodeficiencies and lysosomal storage disorders, providing strong
evidence of safety and long-term efficacy in most cases.5 Gene
therapy for SCD faces additional challenges: although the size of
the gene expression cassette has been reduced to a minimum in
currently used vectors, LCR-b-globin vectors remain complex and
have a lower transduction efficiency in HSCs compared with
simpler vectors. The clinical history of allogeneic HSC transplanta-
tion provides some predictions about the minimal level of corrected
HSCs necessary to achieve clinical benefit.6–8 Recent gene therapy
clinical trials showed, however, that the reduced output of a vec-
tor-borne transgene with respect to the natural b-globin allele
significantly increases the minimal chimerism necessary to achieve
clinical efficacy.12,23 In addition, vector-derived b-globins must
compete for a chains with the output of two endogenous b-globin
genes in order to reduce sickling, requiring higher VCNs in the
transduced cell products. SCD is therefore a more demanding
context with respect to b-thalassemia, where substantial clinical
benefit has been achieved with the current b-globin vectors.13,24,25
Innovation in vector design, HSC procurement, cell manufacturing,
and conditioning regimens appear necessary to achieve the efficacy
required to cure SCD.
In an attempt to increase both transduction efficiency and
anti-sickling activity of the therapeutic LV, we decided to use
the bAS3 gene carrying three different anti-sickling mutations,
T87Q, G16D, and E22A.14 The mutations interfere with both
axial and lateral contacts of b-chains within the HbS polymer
and also increase affinity for the a chains, potentially providing
a higher anti-sickling activity compared with the single T87Qber 2018
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Figure 6. Clonal Dynamics in BM Cells of Transplanted NSG Mice
Relative proportion of reads accounting for each individual IS in pre- and post-transplant samples from individual NSG mice. The gray area in the bars indicates ISs
accounting for <1% of the total in each sample. Individual ISs >1% are color-coded. Three ISs showed read counts >10% in the BM of mice 26, 27, and 30 in the TD1 group
(see also Table S5), in line with lower transduction level and VCN in TD1 CD34+ cells with respect to TD2.
www.moleculartherapy.orgmutant globin carried by the vector currently in clinical develop-
ment.12 The bAS3 gene was inserted in the GLOBE vector,
which contains the HS2 and HS3 elements of the LCR and
lacks HS4, which has a detrimental effect on LV titer and infec-
tivity.26 The enlarged size of the HS2 element increases its
enhancing activity and compensates for the absence of HS4.27
Overall, the GLOBE vector has a reduced size and a relatively
higher titer and infectivity with respect to more complex vector
containing HS4 and the b-globin 30 enhancer, and shows unsur-
passed clinical efficacy in transfusion-dependent b-thalassemia
patients.25
The GLOBE-AS3 vector transduced mobilized CD34+ HSPCs at
high levels, as estimated by overall VCN in the transduced bulk cul-
ture and by analysis of individual clonogenic progenitors differen-
tiated in vitro. HPLC analysis of globin chains in erythrocytes
differentiated from transduced HSPCs obtained from the BM of
SCD patients showed that GLOBE-AS3 drives bAS3-globin expres-Molecular Thesion at potentially therapeutic levels (>30%6–8) and corrects to a
significant extent the sickling phenotype in an in vitro assay. The
level of phenotypic correction was linearly correlated with the
average VCN in the bulk culture, indicating that two or more vec-
tor copies per genome are probably necessary to approach thera-
peutic efficacy, an estimate supported by the available clinical
data.12,23 A VCN of 2 was obtained in the majority of the SCD
donors in the study in standard transduction conditions, an effi-
ciency that can be further improved in a clinical transduction
setting by using plerixafor-mobilized cells28 and adding hormones
or adjuvants to the transduction medium. Combined to the prelim-
inary results coming from the b-thalassemia clinical trial,25 these
data indicate that GLOBE-AS3 is a promising vector for gene ther-
apy of SCD.
Vector IS analysis carried out on transduced HSPCs showed canon-
ical LV integration patterns, with the majority of integrations occur-
ring within genes and the expected high frequency of targeting of arapy: Methods & Clinical Development Vol. 11 December 2018 175
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Figure 7. Clonal Sharing in BM Cells of Transplanted NSG Mice
Only a few ISsmapped in the post-transplant BM samples were identified also in the
corresponding pre-transplant cells because of the highly polyclonal composition of
both TD1 (A) and TD2 (B) samples. Interestingly, some ISs were shared by different
mice in each transduction group, suggesting a number of NSG-repopulating cells
expanded before transplantation and were able to repopulate more than one
mouse.
Molecular Therapy: Methods & Clinical Developmentdefined sub-set of “hot” genes, as previously reported for other LVs in
pre-clinical and clinical studies.29 The list of over-targeted genes was
consistent between two different transduction batches, showed no
bias for particular functional categories of genes, and contained
most of the genes previously reported as over-targeted in clinical
studies of gene therapy for hematological and non-hematological
disorders.29–32 These results indicate that the GLOBE-AS3 vectors
do not deviate from the known LV integration biases in HSPCs,
which depend on the epigenetic and topological features of chro-176 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemmatin in this cell type.29 An IVIM study showed low genotoxicity
in vitro in a sensitive clonal cell proliferation assay, showing no de-
parture from what was previously reported for clinical LVs by the
same assays. This indicates that the combination of LCR-derived el-
ements and b-globin promoter assembled in GLOBE-AS3 has very
low gene activation potential in undifferentiated hematopoietic
progenitors.
As part of the pre-clinical validation of the vector, we analyzed
engraftment, biodistribution, and in vivo genotoxicity of trans-
duced human HSPCs mobilized from healthy donors after xeno-
transplantation in an NSG mouse model. Vector integration
analysis at the end of the study showed that BM repopulation
was sustained by a largely polyclonal repertoire of HSCs, with no
signs of vector-driven clonal dominance and no significant selec-
tion of cells carrying integration in specific genes, as evaluated by
comparing pre-transplant and post-transplant dataset in individual
animals. Unexpectedly, we found a few integrations in common
among different mice transplanted with the same transduced cell
batch, suggesting that at least some NSG-repopulating cells do
expand in the pre-activation and transduction culture period
without losing repopulation capacity. Alternatively, although less
likely, these findings may indicate that LVs have a certain probabil-
ity of integrating at exactly the same nucleotide in different repo-
pulating cells. Interestingly, we observed a slight but significant
reduction in intragenic integrations in NSG-repopulating cells
with respect to pre-transplant HSPCs, indicating a negative in vivo
selection of cells carrying integrations in exons and introns. Inte-
grations in exons cause mono-allelic gene knockout, whereas the
presence of LV proviruses in introns may induce post-transcrip-
tional alterations of gene expression through the insertion of
splicing and polyadenylation signals in primary transcripts, as
previously reported.33,34 These data suggest that some integration
events may reduce cell fitness in vivo and be counter-selected
when occurring in repopulating HSCs. Nevertheless, we observed
no significant differences in the categories of genes targeted by
LV integration before and after transplantation, indicating that if
intragenic integrations cause reduction of cell fitness they do so
in a relatively random fashion.
Overall, based on the prediction power of the in vitro and in vivo
tests used in our study, the safety profile of the GLOBE-AS3 vector
appears comparable with that of any other clinical LV. Combined
with an accurate selection of the target cell population, state-of-
the-art cell processing, and a patient conditioning regimen, the
safety profile, transduction efficiency, and anti-sickling activity of
GLOBE-AS3 pave the way to its clinical development in gene ther-
apy for SCD.
MATERIALS AND METHODS
Vector Production and Titration
LVs pCCL_HS2+HS3_bp_bAS3 (GLOBE-AS3) and pCCL_PGK-
GFP (PGK-GFP) were produced by co-transfection of HEK293T cells
with CMV-GAG/POL, CMV-REV, and CMV-VSV-G plasmids inber 2018
www.moleculartherapy.org225-cm2 tissue culture flasks. After collection of the viral supernatant
24 and 48 hr post-transfection, the virus was concentrated by ultra-
centrifugation and resuspended in X-VIVO 20 medium (Lonza).
For the IVIM and the animal study, GLOBE-AS3 was produced by
transfection of HEK293T in cell factories (CF10), purified by ion-
exchange chromatography, concentrated by tangential-flow filtration,
and formulated in X-Vivo 20 medium, with a process identical to
that used to produce clinical-grade vectors in good manufacturing
practice (GMP) conditions. The viral titer was calculated by transduc-
tion of a standard human colorectal carcinoma cell line (HCT116)
with serial dilution of the viral preparation, followed by VCN
determination.
Human Cell Transduction and Transplantation into NSG Mice
CD34+ cells were isolated from G-CSF-mobilized PB samples
provided by the Centre Hospitalier Sud Francilien (Evry, France) or
by the Institut Gustave Roussy (Paris, France), under full informed
consent. CD34+ cells were immunoselected with the CliniMACS
CD34 reagent system (Miltenyi Biotec) following the manufacturer’s
instructions, pre-activated by overnight culture in X-vivo 20 (Lonza)
containing 300 ng/mL human stem cell factor (SCF) (CellGenix),
300 ng/ml human Flt-3 ligand (CellGenix), 100 ng/mL human
thrombopoietin (TPO) (CellGenix), and 20 ng/mL human inter-
leukin-3 (hIL-3) (CellGenix). For the in vitro study, cells were trans-
duced overnight with increasing MOI of LV-bAS3 and maintained in
myeloid or erythroid differentiation media. Myeloid differentiation
medium was formulated as X-vivo 20 medium containing 50 U/mL
penicillin, 50 ng/mL streptomycin, 100 ng/mL human SCF (hSCF),
100 ng/mL hFlt-3 ligand, 100 ng/mL hTPO, and 20 ng/mL hIL-3.
Erythroid differentiation medium was composed of StemSpan me-
dium supplemented with 50 U/mL penicillin, 50 ng/mL streptomycin,
20 ng/mL hSCF, 1 U/mL human erythropoietin (hEPO), 5 ng/mL
hIL-3, 2 mM dexamethasone, and 1 mM b-estradiol. Cells were main-
tained in differentiation medium for 12–14 days at a density of 0.3–
0.5  106 cells/mL, with media changes every second or third day,
as needed. At the end of culture, 0.5–1  106 cells were pelleted for
DNA or RNA extraction.
For the animal study, cells from three different donors were used and
transduced in two individual transductions, TD1 (MPB_16-06_W)
and TD2 (pool of MPB_16-05_M and MPB_15-04_M). Cells under-
went two hits of transduction (24 hr each) with the LV-bAS3 vector
at an MOI of 100 in the same medium at the concentration of 1 
106 cells/mL, in the presence of protamine sulfate (4 mg/mL; Sigma-
Aldrich). After transduction, cells were washed and transplanted into
sub-lethally irradiated NSG recipient mice. An aliquot of transduced
cells was maintained in liquid culture in myeloid medium for 1 week,
or grown as individual progenitors in semi-solid Methocult medium
(H3434; STEMCELL Technologies) for 2 weeks. Individual colonies
were counted under an inverted microscope after 1 week of culture,
andcollected forVCNevaluationat 2weeks (50 coloniesper condition).
Nine-week-old female NSG mice (Jackson Laboratory Stock No.
005557, supplied by Charles River) were hosted at the Genethon an-Molecular Theimal facility at CERFE (Evry, France) in accordance with all national
and European ethical guidelines. Transduced human CD34+ cells
(2  106 cells/mouse) were administered intravenously by retro-
orbital injection to NSG female mice, which were given 1.5 Gy total
body irradiation as a single dose, 3 hr before transplantation.
Animal study protocols were drafted in accordance with French and
European legislation on animal experimentation and approved by the
Genethon Institutional Animal Care and Use Committee.
Flow Cytometry
Erythroid differentiation was tested by flow cytometry after immuno-
staining for CD36 (Ab 656151; BD Pharmingen) and CD235a (Ab
563666; BD Pharmingen). Donor cell chimerism in total BM cells
was tested by flow cytometry after immunostaining for human-
specific CD45 (Ab A74763; Beckman Coulter). Human T, B, and
myeloid phenotype in total BM and PB cells of transplanted mice
was tested by flow cytometry after immunostaining for the human-
specific CD45 and cell-specific antigens. For the analysis, cells were
resuspended in PBS and incubated for 30 min at 4C with antibodies
for specific antigens or with isotype control following the manufac-
turer’s instructions. Stained cells were washed and measured on BD
LSR II flow cytometer (BD Biosciences). Analyses were performed
with the FlowJo software v7.6.5.
VCN Evaluation
Genomic DNA from transduced cells expanded in liquid culture was
extracted using the Wizard genomic DNA purification kit (Prom-
ega) following the manufacturer’s instructions. Genomic DNA
from hematopoietic colonies was extracted using Proteinase K
(Thermo Fisher Scientific) lysis by adding 20 mL of lysis buffer
(0.3 mM Tris HCl [pH 7.5]; 0.6 mM CaCl2; 1.5% glycerol; 0.675%
Tween 20; and 0.3 mg/mL Proteinase K). Lysis was performed at
65C for 30 min, 90C for 10 min, and 4C for 10 min. Finally,
30 mL of water was added to each sample. The VCN (vector genome
per diploid genome [vg/dg]) was analyzed by duplex TaqMan qPCR
with primers and probes annealing to the HIV psi sequence and a
reference gene, the human ALB gene. Results were calculated based
on a standard curve of a plasmid containing the two sequences. All
PCR measurements were performed at least in duplicates in an ABI
PRISM 7700 system (Thermo Fisher Scientific). All primer and
probe sequences are listed in the Supplemental Materials and
Methods.
Statistical Analysis
Statistical analyses in the results of the animal study were performed
using GraphPad Prism version 7.0 for Windows. Results are reported
as mean ± SE. Statistical differences between means were evaluated by
Mann-Whitney or c2 test as appropriate. Differences were considered
significant at p value <0.05.
Analysis of mRNA Expression
The bAS3 transgene expression was measured in transduced
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Kit (QIAGEN) following the manufacturer’s instructions and
treated with DNase (QIAGEN). Reverse transcription and qRT-
PCR were performed with the LightCycler Multiplex RNA Virus
Master Kit (Roche) according to the manufacturer’s instructions.
Duplex qPCRs with TaqMan probes were performed with primer
pairs amplifying the AS3 transgene (but not the wild-type HBB
sequence) and a normalizer gene (a-globin). Primers and probes
are listed in the Supplemental Materials and Methods.
IVIM Assay
The IVIM assay was performed as previously described.18,19,21 We
transduced 1  105 cells and expanded them for 2 weeks, prior to
limiting dilution replating with 100 cells per 96-well. VCN measure-
ment was performed on day 4 after transduction. The MTT assay was
used for quantification of cell proliferation in 96-well plates.35 For
determination of wells with proliferation, we used the highest
absorbance value of the respective Mock plates, which were below
a previously determine clonal proliferation level (5.61-fold the absor-
bance value of microscopically confirmed negative wells). Based on
meta-data from positive and negative controls of previous assays,
we defined values between the lower limit of detection (LOD =
1.05  104) and a Q1 quantification limit (RF = 34.17  104) as
background.
Viral IS Recovery and Analysis
LTR vector-genome junctions were amplified by restriction-based or
sonication-based LM-PCR. In the restriction-based method, 1 mg of
genomic DNA was digested 6 hr at 37C with the Tru91 restriction
enzyme (Roche), purified by NucleoSpin Gel and PCR Clean-up kit
(MACHEREY-NAGEL) and ligated overnight to a TA-protruding
double-stranded DNA linker by T4 DNA Ligase (New England Bio-
labs). Ligated DNA was purified, digested overnight at 37C with SacI
(Roche), and purified again.
Multiple nested PCRs (10–20) were performed with specific
primers annealing to the linker and the 30 vector LTR, adapted
to Illumina sequencing and containing a 4-bp sample-specific
barcode for sample identification. Libraries were quantified on
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific)
and loaded on a 1% agarose gel for amplicon size selection. Ampli-
cons ranging from 200 to 500 kb were manually extracted from the
gel and purified by NucleoSpin Gel and PCR Clean-up kit. About
1 mg of the final libraries were subsequently processed with MiSeq
Reagent Kit v3 (2  300 bp pair-end sequencing) following the
manufacturer’s instructions, bar-coded with a 6-bp sample-specific
tag, and sequenced to saturation on an Illumina MySeq machine at
IGA Technology Services (Udine, Italy). Raw reads resulting from
Illumina paired-end sequencing were bioinformatically trimmed to
recover the human genome sequences adjacent to the 30 proviral
LTR by the Skewer software (mismatch rate of 0.12, minimal
length of 20 bp after trimming, and a minimal match length equal
to the pre-trimming sequence) and mapped on the reference
genome (human GRCh37.75/hg19) by the Bowtie2 software178 Molecular Therapy: Methods & Clinical Development Vol. 11 Decem(>95% identity). The genomic coordinates of the first nucleotide
in the host genome adjacent to the viral LTR were indicated
as ISs. ISs originated by different reads mapping in the same
genomic position were collapsed recovering the number of corre-
sponding reads (read count). Unique ISs were annotated on the
RefSeq gene database as intergenic or intragenic (exonic or in-
tronic). Genes (defined by the most upstream transcription start
site to the most downstream 30 end) hosting at least one IS were
identified as target genes. Genes with targeting frequency signifi-
cantly higher than random, defined by 200 random sampling of
virtual ISs corresponding to 5,330,124 and 5,812,911 Tru91 sites
in the human and murine genome, respectively, were defined as
over-targeted, after Bonferroni correction of the comparison
p values. Genes with at least three ISs and a Bonferroni-corrected
p value <0.001 were defined as over-targeted. Additional informa-
tion about the bioinformatics processing of the sequencing reads
can be found in the Supplemental Materials and Methods.
Sequencing reads are available at Sequence Read Archive (SRA):
PRJNA497990.
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